Market News How it works Learn FAQ
| RCT 0.1222 60.58% | NU 12.375 -18.37% | EWZ 33.44 -21.48% | TGL 0.2449 10.56% | BBD 2.87 -29.48% | SRTM 0.3384 -21.36% | ITUB 7.555 -21.87% | AZTR 1.72 140.56% | XP 15.775 -48.13% | NVD 4.02 -4.06% | SHFS 0.0979 -26.06% | SPCX 148.81 0.89% | CLRO 4.75 46.15% | SOXL 90.94 8.83% | GCDT 0.1442 -18.11% | PBR 22 -15.90% | NWGL 0.0822 0.24% | VALE 11.895 -4.07% | TSLL 10.9402 12.09% | INTC 90.94 4.58% | SGRY 23.095 46.63% | CRWV 56.79 4.71% | NVDA 215.6 2.20% | BITO 10.6301 -1.85% | GPUS 0.1862 10.24% | SOXS 47.855 -8.78% | RBNE 0.17 -10.53% | NOK 8.6738 6.56% | ABEV 2.78 -15.76% | RWM 14.455 -0.65% | IREN 26.12 4.88% | JBLU 2.2648 -13.72% | INTR 4.525 -37.07% | TSLG 5.4701 12.32% | SBS 4.615 -27.89% | TQQQ 68.649 3.56% | XTND 2.1 18.64% | SPRC 1.5 37.61% | SPDN 8.4901 -0.58% | TSLA 395.035 6.13% | AAL 12.1593 0.41% | LUCD 0.5437 32.29% | SID 0.9326 -20.97% | SQQQ 38.275 -3.54% | PBR-A 19.3171 -17.90% | CIFR 7.9 -0.50% | GGB 4.725 -7.35% | T 21.035 0.50% | QID 14.195 -2.44% | NFLX 63.265 -3.93%
EVEvotec SE logo

Evotec SE (EVO)

NASDAQ Global Select · Currency in USD
$1.52 ▲ +0.02 (+1.33%)
As of Oct 26, 1:19 PM ET. Market open.

Summary

Previous Close
$1.50
Open
$1.52
Day's Range
$1.51 – $1.53
52 Week Range
$1.33 – $4.27
Volume
114,047
Avg. Volume
91,819
Market Cap
$539.88M
Beta (5Y Monthly)
1.26
PE Ratio (TTM)
--
EPS (TTM)
-$0.55
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
$3.47 (228.00%)
Ex-Dividend Date
Jan 11, 2019
1y Target Est
$3.00

Profile: Evotec SE

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
4,553
CEO
Christian Wojczewski
Website
evotec.com

Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.20 · Revenue est. $155.05M
DateEst.Actual
Aug 13, 2026-$0.05-$0.17Miss
May 6, 2026-$0.15-$0.46Miss
Apr 8, 2026$0.21$0.05Miss
Nov 5, 2025-$0.14-$0.14Miss
Aug 13, 2025-$0.18-$0.14Beat
May 6, 2025-$0.11-$0.15Miss

Analyst view

Consensus price target
$3.00 ▲ +97.4%
Range $2.00 – $4.00
Rating: Buy
Buy 57% · Hold 43% · Sell 0%

Get free alerts on EVO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.